The Data Decision Log That Life Sciences Partnerships Need
A laboratory sends a corrected biomarker report after a study site has acted on the original classification. The corrected record reaches the sponsor’s database, but the eligibility list and an earlier program report still carry the first result. Each system has a record of its own activity. The partnership lacks a shared account of the decision and its consequences.
This hypothetical example shows a gap that access policies and data dictionaries cannot close on their own. The teams need to agree which interpretation governs, who has authority to decide, which outputs are affected, and what must happen next. A record marked “resolved” is inadequate if the correction has not reached the people using it.
In my work across therapeutic development, diagnostics, and partnerships, the handoff between organizations has often required as much attention as the individual deliverable. A data decision log provides a practical record for consequential interpretations that cross those boundaries. It links the question, evidence, decision owner, implementation, and conditions for reconsideration.
The log belongs alongside established clinical data and quality processes. It should make a cross-partner decision easier to inspect without becoming a second source system or an informal substitute for controlled approval.
A data dictionary does not resolve every dispute
A dictionary might define “sample collected,” “assay valid,” or “site activated.” In practice, a result can be more complicated. A specimen may have been collected during routine care before trial consent, processed after a protocol amendment, or tested with a version of the assay that later changes. The data field has a definition, but the team still must decide how that record affects eligibility, analysis, or a quality investigation.
The decision log should not replace the dictionary, protocol, or controlled procedures. It should link to them and record how the team resolved a specific ambiguity. A useful entry states the question, affected data, applicable documents and versions, competing interpretations, decision authority, chosen interpretation, effective date, and downstream consequences. It should distinguish a temporary operational rule from a formal change requiring approval.
The log should have a narrow scope. Routine corrections belong in the source system and its audit trail. A decision log is for interpretations that can alter an important measure, patient selection, evidence package, or external commitment. If every spelling correction becomes a governance meeting, the mechanism will be ignored.
The first challenge is agreeing on what counts as consequential. A disagreement over one record may be material if it changes a patient classification near a biomarker threshold. A discrepancy across hundreds of records may be less material if it does not affect the intended analysis. The team should define materiality by decision impact, not record count alone.
Roche’s May 2026 agreement to acquire PathAI illustrates the industry’s interest in bringing digital pathology, biomarker work, and companion diagnostics together. The public announcement describes that direction, not the performance of a particular joint development program. In a collaboration using those capabilities, an interpretation can cross therapeutic, laboratory, and software boundaries. A shared decision record is one way to keep the applicable evidence and authority visible at each handoff. [4]
Follow the information from source to action
Consider a hypothetical program using a biomarker test to determine study eligibility. A site collects tissue, a courier transports it, a laboratory receives and assesses it, an assay produces a score, and a clinical system receives the reported classification. The study team then decides whether the person can enroll.
At each handoff, meaning can change. “Received” may refer to arrival at a shipping hub or accession at the laboratory. A test run can be technically complete but invalid under the quality criteria. A revised report may supersede a preliminary result after the site has already acted. A specimen identifier may be corrected after the result is transferred.
Map each point where a data value informs a decision. The map should identify the authoritative system, timestamp, version, and responsible person or function. It should state whether a downstream team receives an update when the source changes. A data pipeline that transfers the first report but not an amended report can be technically reliable while clinically wrong.
The decision log records exceptions to the agreed rules. If a site asks whether a preliminary result can support screening, the answer should not live only in an email between two individuals. The team needs a controlled interpretation, its scope, and a path for notifying everyone whose workflow depends on it.
The same structure applies beyond diagnostics. A manufacturing partner may report a batch status using its own milestones. A CRO may call a site active when contracts are complete, while the sponsor means ready to enroll. A digital health provider may call a measurement complete when uploaded, although quality checks later exclude it. The words are familiar; the operational states differ.
Give each decision a clear owner
Partnership agreements name organizations, yet a data disagreement needs a person or function empowered to resolve it. Technical staff may identify an issue without authority to change a clinical rule. Clinical staff may understand the consequence without knowing the source-system behavior. Regulatory or quality teams may need to approve a controlled change rather than merely be informed afterward.
Three roles need to be explicit. The issue owner investigates and assembles the facts. The decision owner accepts the interpretation within a specified scope. The implementation owner updates systems, documents, and affected teams. These can be different people. A single accountable name for each role avoids an unresolved issue circulating across a committee.
Escalation should reflect risk and timing. A question that could change enrollment tomorrow may need a same-day route. A nonurgent reconciliation rule for a future analysis can be reviewed in a scheduled forum. The operating model should state who can make an interim decision, how it is recorded, and when formal approval is required.
Cross-organization contracts should support this process. They can require timely notice of corrected records, access to relevant audit history, cooperation in root-cause investigation, and agreed turnaround for material issues. The contract need not anticipate every ambiguity. It should make it possible to resolve one without arguing first about who is allowed to see the evidence.
FDA’s electronic source data and electronic systems guidance provide the regulatory context for reliable and traceable clinical records. The decision log proposed here is an operating recommendation; those documents do not prescribe this particular format. It should link to established records and procedures rather than replace them. [1, 2]
Record what was known at the time
A decision made in March may look questionable in June if the underlying data were later corrected. The log should preserve what information was available at the decision time. It should link the decision to source versions and identify later updates. This allows the team to distinguish a reasonable decision under the evidence then available from a process failure that should have been detected.
Time is not one field. Source creation, clinical event, laboratory receipt, system entry, approval, transmission, and effective dates can differ. A record that arrived in an analysis environment on Tuesday may describe a patient event from the prior month. Governance should specify which timestamp answers which question.
If a revised assay report changes a classification, the team should be able to identify the original report, revised report, reason for correction, recipients, and actions taken under each. Simply overwriting the earlier value destroys the chain needed for clinical and quality review.
Version control extends to reference information. Protocol amendments, assay instructions, case report forms, endpoint definitions, and data transformations may change. The log should state the version governing a decision. Without this, a team can apply today’s rule to yesterday’s record and present an apparently consistent but historically inaccurate result.
Get Ashish Yadav’s stories in your inbox
Join Medium for free to get updates from this writer.
This is particularly important when different partners work on different update cycles. One partner may deploy a data mapping weekly while another changes a controlled document quarterly. A common calendar of changes and effective dates reduces the risk of silent divergence.
Separate correction from reinterpretation
If a value was entered incorrectly and the source can be verified, a correction may follow an established data management process. If the source is accurate but the team disagrees about what it means, the issue is interpretive. The distinction affects approval, traceability, and communication.
Suppose a laboratory reports a valid numerical score but the sponsor’s integration applies an outdated cutoff. The source score may be correct; the derived classification is not. Fixing a mapping may require assessing every affected record and any actions taken on the previous classification. A decision log can capture scope and remediation, while the technical audit trail captures the actual correction.
Now suppose experts disagree over whether a borderline specimen meets an established quality criterion. That may require a scientific and quality determination, not a database patch. The outcome and rationale should be documented at the level appropriate to the program. A script that forces the preferred classification would conceal the underlying judgment.
The issue owner should identify whether the problem is a source error or a disputed interpretation. This prevents meetings from jumping immediately to an IT fix for a clinical ambiguity or from escalating a simple source correction into a new policy debate.
Design the log for use not display
A practical log needs a small number of required fields and links to authoritative evidence. It should support search by program, dataset, decision type, and status. Sensitive details should remain in the appropriate controlled system, with access governed by role. The log can point to records without copying confidential patient or partner information into a broad collaboration tool.
The log needs an “affected outputs” field. If a decision changes a dashboard, eligibility list, analysis dataset, regulatory figure, or partner report, those artifacts should be identified and updated or clearly marked. A resolved issue is not truly resolved while downstream reports still use the old rule.
The log should have a review date where uncertainty remains. An interim interpretation may be reasonable while awaiting assay data or a formal protocol change. It should not become permanent simply because the team forgot its temporary status.
The organization should also avoid using the log as a substitute for formal quality processes. An adverse event, deviation, complaint, or controlled document change may have a prescribed route. The log can link to that route and show the cross-partner decision, but it should not create a competing unofficial record.
Measure whether it improves the partnership
Counting log entries is a weak measure. A rise in entries could mean better detection or a deteriorating data process. Track time from issue identification to a decision, unresolved material issues at key milestones, repeated disputes over the same definition, downstream corrections, and the proportion of decisions communicated to all affected partners.
Periodically sample entries for quality. Could an independent reviewer understand the question, evidence, authority, and action? Are temporary decisions revisited? Did the resolution reach systems and people who depend on it? These checks reveal whether the log is a living control or a repository of meeting minutes.
Patterns can expose structural problems. If many issues concern site status, the partners may need a better shared state model. If amended laboratory reports repeatedly fail to reach sites, a feed and notification process needs repair. The log’s value lies partly in identifying root causes that a series of one-off fixes would hide.
This can improve relationship quality. Partners are less likely to interpret every disagreement as poor performance when there is a fair process for evidence and resolution. Accountability becomes clearer without assuming bad intent. The discussions focus on the patient or program decision affected by the data.
A ninety day introduction
Introduce the log in one collaboration and two or three decision types. Start with a short workshop to map the source-to-decision chain. Agree on terms that already cause disagreement, identify decision owners, and set escalation times. Use an existing controlled tool where possible rather than buying software first.
During the first month, record only material ambiguities and review the format weekly. In the second, assess whether decisions reach downstream systems and teams. In the third, review recurring themes and decide which definitions or data contracts should be changed. This sequence produces a practical operating process, not another governance policy that people learn about after an incident.
Test the process with a realistic example before relying on it. Ask how the team would handle a corrected biomarker result after a site acted on the original report. If nobody can identify the owner, recipients, and affected records, refine the route. The exercise is valuable even if that exact event never occurs.
The log does not eliminate judgment. It makes judgment inspectable and actionable across organizations. That is a useful standard for data governance in a partnership: the right people can see the evidence, understand the interpretation, implement it consistently, and revisit it when new information arrives.
When the data decision affects a submission
The log becomes especially valuable when a discrepancy is found after an analysis or document has been assembled. The team needs to identify which outputs use the affected interpretation and whether the change is material to a conclusion. A line in an issue tracker that says “resolved” does not tell a reviewer whether tables, figures, listings, or narrative statements were assessed.
The resolution needs a short impact assessment: affected records and time period, prior and corrected rule, outputs reviewed, decision maker, and disposition. If no output changes, record why. If an output changes, preserve the earlier version and the approval trail. This provides a defensible history without turning every correction into a crisis.
The same discipline helps when an external partner changes its system. A new software release may alter a field name or export format while leaving the displayed values apparently familiar. A regression check should compare representative records and derived measures. If differences arise, the decision log can connect the technical finding to the clinical or regulatory choice it affects.
At a submission milestone, the question is whether the team can account for the conclusions it presents. A timely record of interpretation and implementation helps establish that account. It also preserves the reasoning for colleagues who join the program later and need to understand why an apparently simple field is governed by a particular rule.
Sources
[1] U.S. Food and Drug Administration. Electronic Source Data in Clinical Investigations (2013). Source
[2] U.S. Food and Drug Administration. Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers (final guidance, October 2024). Source
[3] Clinical Data Interchange Standards Consortium. Foundational standards. Source
[4] Roche. Definitive merger agreement to acquire PathAI (May 7, 2026). Source
